February 28, 2025

New Publication from CeMOS: Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

New Publication from CeMOS: Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

Müller, E.; Enzlein, T.; Niemeyer, D.; von Ammon, L.; Stumpo, K.; Biber, K.; Klein, C.; Hopf, C. Exploring the Aβ Plaque Microenvironment in Alzheimer’s Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer. Pharmaceuticals 202518, 252. https://doi.org/10.3390/ph18020252

Abstract

Amyloid-β (Aβ) plaque deposits in the brain are a hallmark of Alzheimer’s disease (AD) neuropathology. Plaques consist of complex mixtures of peptides like Aβ1–42 and characteristic lipids such as gangliosides, and they are targeted by reactive microglia and astrocytes. Background: In pharmaceutical research and development, it is a formidable challenge to contextualize the different biomolecular classes and cell types of the Aβ plaque microenvironment in a coherent experimental workflow on a single tissue section and on a benchtop imaging reader. Methods: Here, we developed a workflow that combines lipid MALDI mass spectrometry imaging using a vacuum-stable matrix with histopathology stains and with the MALDI HiPLEX immunohistochemistry of plaques and multiple protein markers on a benchtop imaging mass spectrometer. The three data layers consisting of lipids, protein markers, and histology could be co-registered and evaluated together. Results: Multimodal data analysis suggested the extensive co-localization of Aβ plaques with the peptide precursor protein, with a defined subset of lipids and with reactive glia cells on a single brain section in APPPS1 mice. Plaque-associated lipids like ganglioside GM2 and phosphatidylinositol PI38:4 isoforms were readily identified using the tandem MS capabilities of the mass spectrometer. Conclusions: Altogether, our data suggests that complex pathology involving multiple lipids, proteins and cell types can be interrogated by this spatial multiomics workflow on a user-friendly benchtop mass spectrometer.

Our latest News

discover more
EMBL Council announces next EMBL Director General

EMBL Council announces next EMBL Director General

Anthony A. Hyman’s mandate to commence 31 March 2026 At its winter meeting, EMBL Council selected Anthony A. Hyman as EMBL’s next Director General.  “I am pleased to announce the decision by the EMBL Council to elect Anthony Hyman as future EMBL Director General,” said Peter Becker, EMBL Council Chair. “Tony witnessed the spirit of […]

SPT Labtech enables automated PacBio Kinnex full-length RNA-seq library preparation workflow on SPT’s firefly platform

SPT Labtech enables automated PacBio Kinnex full-length RNA-seq library preparation workflow on SPT’s firefly platform

Cambridge, UK, 20 November 2025: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, today announced a collaboration with Pacific Biosciences (PacBio), a pioneer in long-read sequencing, to automate PacBio’s Kinnex™ full-length RNA-seq library preparation on SPT Labtech’s firefly® liquid handling platform. The automated workflow will improve reproducibility […]

Ovesco takes the next step in metabolic bariatric endoscopy and invests in Transduodenal Concepts

Ovesco takes the next step in metabolic bariatric endoscopy and invests in Transduodenal Concepts

Ovesco Endoscopy AG from Tübingen is investing almost € 1 million in the company Trans-Duodenal Concepts GmbH, Mannheim, to jointly promote innovative solutions in the field of metabolic-bariatric endoscopy. Around one billion people worldwide are affected by metabolic syndrome and its manifestations such as obesity, diabetes, hypertension and fatty liver disease. The Mannheim-based start-up Trans-Duodenal […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp